Reata Pharmaceuticals Profit Margin

The latest profit margin for RETA is -350.36% as of June 2023. That compares with -3045.98% in the prior-year period — up 88.5% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Reata Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, RETA's profit margin moved from -3045.98% to -350.36% — a 88.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Reata Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, RETA currently prints -350.36% for profit margin, while the sector average sits near 13.89%. That is roughly 2621.8% below the sector mean. Large gaps often invite a closer look at Reata Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Reata Pharmaceuticals converts resources into returns. At -350.36%, RETA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3045.98% in the prior-year period — up 88.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RETA's profit margin (-350.36%), review year-over-year change from -3045.98%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.